Obiettivo
Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SCID) have been successfully treated by autologous stem cell based gene therapy. However, for the most common group of SCID, the SCID underlying recombination defects, this has not yet occurred due to the higher complexities of the affected genes involved. The aim of the current proposal is to fill the unmet medical need for the most common major category of SCID, recombination activating gene-1 (RAG-1) deficient SCID, by performing Stage I/II clinical trials using autologous hematopoietic stem cell based gene therapy. To this end we will develop novel safety assays, pre-GMP and GMP lentiviral batches and design and conduct multicenter, multinational clinical trials with input from regulatory authorities such as EMA and patient advocacy groups. The trial will be conducted with phenotypic, molecular (integration sites, therapeutic gene expression) and functional readouts and should lead to effective treatment for > 70% of all SCID patients in Europe. RECOMB forms the logical extension of highly successful previous EU consortia that have made the EU global leader in gene therapy for orphan immune diseases.
Campo scientifico
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineemergency medicinegraft versus host disease
- medical and health sciencesclinical medicinetransplantation
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2017-Two-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
2333 ZA Leiden
Paesi Bassi
Mostra sulla mappa
Partecipanti (16)
75654 Paris
Mostra sulla mappa
WC1E 6BT London
Mostra sulla mappa
WC1N 3JH London
Mostra sulla mappa
20132 Milano
Mostra sulla mappa
30625 Hannover
Mostra sulla mappa
89081 Ulm
Mostra sulla mappa
50 367 Wroclaw
Mostra sulla mappa
NE1 7RU Newcastle Upon Tyne
Mostra sulla mappa
PL11 3LE Torpoint
Mostra sulla mappa
2333 CL Leiden
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
08035 Barcelona
Mostra sulla mappa
00165 Roma
Mostra sulla mappa
75012 Paris
Mostra sulla mappa
52621 Ramat Gan
Mostra sulla mappa
80539 MUNCHEN
Mostra sulla mappa
69120 Heidelberg
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.